🇺🇸 FDA
Patent

US 11572372

Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds

granted A61KA61K31/424A61K31/4355

Quick answer

US patent 11572372 (Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds) held by Medshine Discovery Inc. expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/424, A61K31/4355, A61K31/437, A61P